Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145
PHASE1CompletedINTERVENTIONAL
Enrollment
14
Participants
Timeline
Start Date
October 31, 2013
Primary Completion Date
November 30, 2013
Study Completion Date
December 31, 2013
Conditions
Healthy
Interventions
DRUG
IPI-145
25 mg oral capsule
DRUG
Rifampin
2x 300 mg oral capsule
Trial Locations (1)
66219
PRA International, Inc, Lenexa
All Listed Sponsors
lead
SecuraBio
INDUSTRY
NCT01947777 - Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145 | Biotech Hunter | Biotech Hunter